Indivior Pharmaceuticals (INDV) risk factors, FY2024 10-K

Risks Related to our Company and Its Business

1. 01We are currently, in the past have been, and in the future may be, subject to substantial litigation that could cause us to incur significant legal expenses, divert management’s attention, and result in harm to our business
2. 02particular period. In addition, negative publicity related to these proceedings may negatively impact the Company’s reputation
3. 03We rely on third parties to manufacture, package, test, and distribute our products and their facilities and processes must meet stringent regulatory requirements
4. 04Congressional action to reduce spending may result in cuts to Medicaid which in turn might impair access to our products in the U.S., thereby adversely affecting our revenues and results of operations
5. 05We are subject to additional risks because we import, manufacture, and distribute controlled substances
6. 06We are subject to risks related to the manufacture and distribution of our products globally and must meet stringent current Good Manufacturing Practices
7. 07custody, restricted supply of raw materials or components due to geopolitical disruption or pandemic, and environmental factors
8. 08Our success will also depend in large part on our ability to continue to successfully manufacture and commercialize new products in the complex markets into which they are sold
9. 09Any factors preventing or limiting the market acceptance or commercialization of our products could cause us to recognize charges as we did with PERSERIS and could have a material adverse effect on their sales and hence our business, results of operations and financial condition
10. 10Reimbursement guidelines and incentives provided to prescribing physicians by third party payors may have a significant impact on the prescribing physicians’ willingness and ability to prescribe our products
11. 11products as an alternative to branded products, and/or branded products available through parallel import to keep healthcare costs down
12. 12Our revenues may grow at a slower than expected rate or decrease due to many factors
13. 13Most of our pharmaceutical pipeline relies on collaborations with third parties, which may adversely affect the development and sale of our products
14. 14to comply with these regulations may require us to repeat or redesign clinical trials, which would delay the regulatory approval process or expose us to regulatory sanctions
15. 15Clinical trials for the development of products, including our key pipeline products, may be unsuccessful and our product candidates may not receive authorization for manufacture and sale
16. 16The clinical study or commercial use of our products may cause unintended side effects or adverse reactions, or incidents of misuse may occur, which could adversely affect our products, business and share price
17. 17We face additional risks as a manufacturer that manufactures pharmaceutical products for others and, in the future, for ourselves
18. 18as depreciation of excess capacity, incremental compensation expense from additional headcount, and incremental information technology and other expenses, resulting in expected operating losses for the Raleigh Manufacturing Facility
19. 19If we fail to develop or acquire other new products or compounds for development, our business, prospects, results of operations and financial condition could be materially adversely affected
20. 20See “Item 1.Business —Pipeline,” for more information
21. 21Acquisitions, partnerships, joint ventures, dispositions, and other business combinations or strategic transactions involve several inherent risks, any of which could result in the benefits anticipated not being realized and could have an adverse effect on our business, financial condition, and results of operations
22. 22In the future, our ability to acquire additional companies or products synergistic with our current businesses may be limited by antitrust regulators who may be particularly vigilant in our markets because we serve at-risk populations and because we already market several products in the space
23. 23We may be subject to adverse public opinion
24. 24Failure to retain key personnel or attract new personnel could have a material adverse effect on us
25. 25We use hazardous materials in our manufacturing facilities, and any claims relating to the improper handling, storage, release or disposal of these materials could be time-consuming and expensive

Risks Related to Intellectual Property

1. 26We may incur substantial costs as a result of litigation or other proceedings relating to patents and other intellectual property rights, and we may be unable to protect our rights to, or commercialize our products
2. 27We may not be able to protect our intellectual property rights throughout the world which could have an adverse effect on our business, results of operations and financial condition
3. 28Failure to obtain and maintain patents and protect other proprietary rights, including in-licenses of such rights from third parties, may adversely affect us
4. 29We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers

Risks Related to Regulatory or Legal Matters

1. 30The FDA, the DEA, or other regulatory agencies may impose limitations or post-approval requirements on approvals for our products
2. 31We are subject to ongoing obligations and continued regulatory inspection by the FDA and equivalent foreign regulatory agencies, and we may be subject to penalties and litigation and large incremental expenses if we fail to comply with regulatory requirements or experience problems with our products
3. 32The regulations, policies or guidance of regulatory agencies may change, and new or additional statutes or government regulations may be enacted that could prevent or delay regulatory approval of our product candidates or further restrict or regulate post-approval activities
4. 33Guidelines and coverage determinations published by the government, professional societies, insurance carriers, physician groups, science foundations, and other organizations may affect the use of the Company’s products
5. 34Product liability and product recalls could have a material adverse effect on us
6. 35We are subject to federal, state and foreign healthcare laws and regulations and implementation or changes to such healthcare laws and regulations could adversely affect our business and results of operations
7. 36Failure to comply with payment and reporting obligations under the Medicaid Drug Rebate program or other governmental pricing programs in the U.S. could result in additional reimbursement requirements, penalties, sanctions and fines
8. 37Any of the foregoing could have a material adverse effect on our business, prospects, results of operations and financial condition
9. 38Failure to comply with anti-corruption laws and regulations, anti-money laundering laws and regulations, and/or economic sanctions could result in us becoming subject to fines or penalties
10. 39The pharmaceutical sector is facing increased government scrutiny from competition and pricing authorities around the world, and any failure to comply, may expose us to significant damages and commercial restrictions that can materially and adversely affect our business

Risks Related to our Financial Condition and Tax Matters

1. 40Recently proposed tariffs on pharmaceutical products, and potential reciprocal responses by other countries, may adversely affect our revenues or profitability
2. 41We have limited capacity to raise prices to recover costs of tariffs because, for example, the federal Inflation Reduction Act limits US pharma price increases to no greater than a certain inflation rate, and increases in excess of inflation trigger a 100% excise tax
3. 42Our balance sheet is leveraged, and any reduction in annual sales may adversely affect our liquidity
4. 43Any future pandemic, and governmental and societal responses thereto, may harm our business, results of operations, and financial condition
5. 44Our insurance coverage may not be adequate
6. 45Our term loan contains certain covenants that could limit our ability to plan for or respond to changes in our business
7. 46We may not be able to generate sufficient cash to service all of our indebtedness and may be forced to take other actions to satisfy our obligations under our indebtedness
8. 47Our effective tax rate may increase, and changes in tax rules and regulations, or interpretations thereof, may adversely affect our financial condition
9. 48Our deferred tax assets may not be realized

Risks Related to Our Ordinary Shares

1. 49Our ordinary shares are subject to market price volatility and the market price may decline disproportionately in response to developments that are unrelated to our operating performance
2. 50Our operating results may fluctuate significantly
3. 51Our ordinary shares are listed to trade on more than one stock exchange, and this may result in price variations
4. 52We face a number of risks associated resulting from the relocation of our primary listing
5. 53Provisions of our Note Purchase Agreement and the U.K. City Code on Takeovers and Mergers may deter or prevent an otherwise beneficial takeover attempt of us
6. 54If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our share price and trading volume could decline
7. 55We may not pay dividends or repurchase our shares in the future. Our ability to pay dividends, repurchase our shares, or make other returns of capital in the future depends, among other things, on our financial performance
8. 56The Parent Company is a holding company with no business operations of its own and depends on its subsidiaries for cash, including in order to pay dividends or make share repurchases

Risks Related to Information Security and Data Privacy

1. 57Business interruptions or breaches of data security could disrupt our product sales and delay the development of our product candidates
2. 58We rely on systems, networks, products, and services, some of which are managed by third-party service providers to protect our information. Increased information security threats, more sophisticated cyber-attacks and a growing base of diversified threat actors continually pose a risk to all systems and data

Risks Related to Our International Status and Operations

1. 59We are subject to various risks related to the local and international nature of our business, including domestic and foreign laws, regulations, and standards. Failure to comply with such laws and regulations or the occurrence of unforeseen developments such as litigation could adversely affect our business
2. 60We are exposed to risks related to currency exchange rates
3. 61our exposure to exchange rate fluctuations, our business, financial condition, and results of operations could be materially adversely affected

Risks Related to Being a Publicly-Traded Company in the U.S

1. 62The determination of foreign private issuer status is made annually on the last business day of an issuer’s most recently completed second financial quarter. Accordingly, we will next make a determination with respect to our foreign private issuer status on June 30, 2025
2. 63We have changed the financial reporting standards that we apply to our financial statements from IFRS to U.S. GAAP and, as a result, some of our financial data may not be easily comparable to historical financial results
3. 64Changes in accounting standards and subjective assumptions, estimates and judgments by management related to complex accounting matters, could significantly affect our financial results or financial condition